



Genomic Health, Inc.
Investor Relations Department
301 Penobscot Dr.
Redwood City, CA 94063
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: GHDX

Last Trade:	31.40
Trade Time:	4:00 PM ET Feb 22, 2018
Change:	-2.08 (-6.213%)
Day Range	31.04 - 33.26
52-Week Range	26.54 - 37.50
Volume	306,263


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Feb 22, 2018

[Genomic Health to Announce Fourth Quarter and Year-End 2017 Financial Results and Host Conference Call on Thursday, March 8, 2018](#)

Feb 5, 2018

[Oncotype DX® Genomic Prostate Score™ Test Increases Use of Active Surveillance by 30 Percent in Low-risk Patients, Resulting in Greater Adherence to Guideline-based Care](#)

Dec 21, 2017

[Genomic Health to Present at the 36th Annual J.P. Morgan Healthcare Conference](#)

Dec 11, 2017

[Genomic Health Presents New Data Demonstrating Value of Oncotype DX® to Optimize Breast Cancer Outcomes and Reduce Treatment Burden throughout Disease Continuum](#)

Dec 6, 2017

[Genomic Health Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Oncotype DX® Genomic Prostate Score™ Test for Potential Drug Development](#)

Upcoming Events [\[View all \]](#)

Mar 8, 2018 8:30 AM ET

[Genomic Health Fourth Quarter 2017 Financial Results](#)

Financials & Filings [\[View all \]](#)

Mar 15, 2017

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 9, 2017

[Quarterly Report \(10-Q\)](#)

Aug 4, 2017

[Quarterly Report \(10-Q\)](#)

May 10, 2017

[Quarterly Report \(10-Q\)](#)